RU2486198C2 - Антиген, ассоциированный с ревматоидным артритом - Google Patents

Антиген, ассоциированный с ревматоидным артритом Download PDF

Info

Publication number
RU2486198C2
RU2486198C2 RU2010121874/10A RU2010121874A RU2486198C2 RU 2486198 C2 RU2486198 C2 RU 2486198C2 RU 2010121874/10 A RU2010121874/10 A RU 2010121874/10A RU 2010121874 A RU2010121874 A RU 2010121874A RU 2486198 C2 RU2486198 C2 RU 2486198C2
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
antibody
fragment
Prior art date
Application number
RU2010121874/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2010121874A (ru
Inventor
Мануэла Каспар
Катрин ШВАГЕР
Эвелин Трачсел
Original Assignee
Филоджен С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Филоджен С.П.А. filed Critical Филоджен С.П.А.
Publication of RU2010121874A publication Critical patent/RU2010121874A/ru
Application granted granted Critical
Publication of RU2486198C2 publication Critical patent/RU2486198C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
RU2010121874/10A 2007-10-30 2008-10-27 Антиген, ассоциированный с ревматоидным артритом RU2486198C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98360607P 2007-10-30 2007-10-30
US60/983,606 2007-10-30
PCT/EP2008/009070 WO2009056268A1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2013115891A Division RU2649368C2 (ru) 2007-10-30 2013-04-09 Антиген, ассоциированный с ревматоидным артритом

Publications (2)

Publication Number Publication Date
RU2010121874A RU2010121874A (ru) 2011-12-10
RU2486198C2 true RU2486198C2 (ru) 2013-06-27

Family

ID=40282320

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010121874/10A RU2486198C2 (ru) 2007-10-30 2008-10-27 Антиген, ассоциированный с ревматоидным артритом
RU2013115891A RU2649368C2 (ru) 2007-10-30 2013-04-09 Антиген, ассоциированный с ревматоидным артритом

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013115891A RU2649368C2 (ru) 2007-10-30 2013-04-09 Антиген, ассоциированный с ревматоидным артритом

Country Status (18)

Country Link
US (4) US8222377B2 (cg-RX-API-DMAC7.html)
EP (3) EP2209805B1 (cg-RX-API-DMAC7.html)
JP (3) JP5106635B2 (cg-RX-API-DMAC7.html)
KR (3) KR101836968B1 (cg-RX-API-DMAC7.html)
CN (2) CN101918443B (cg-RX-API-DMAC7.html)
AU (1) AU2008317941B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818272B8 (cg-RX-API-DMAC7.html)
CA (1) CA2704296C (cg-RX-API-DMAC7.html)
DK (2) DK2209805T3 (cg-RX-API-DMAC7.html)
ES (2) ES2807753T3 (cg-RX-API-DMAC7.html)
HU (2) HUE050038T2 (cg-RX-API-DMAC7.html)
MX (1) MX2010004726A (cg-RX-API-DMAC7.html)
NO (1) NO2209805T3 (cg-RX-API-DMAC7.html)
PL (2) PL3281952T3 (cg-RX-API-DMAC7.html)
PT (2) PT3281952T (cg-RX-API-DMAC7.html)
RU (2) RU2486198C2 (cg-RX-API-DMAC7.html)
SI (2) SI3281952T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009056268A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070084556A1 (en) 2005-10-14 2007-04-19 Langseder Neal E Method of applying a label to a squeeze tube
EA036322B1 (ru) 2007-04-02 2020-10-26 Филоджен С.П.А. Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
PT3281952T (pt) 2007-10-30 2020-07-23 Philogen Spa Um antigénio associado a artrite reumatoide
ES2549362T3 (es) 2009-01-07 2015-10-27 Philogen S.P.A. Antígenos asociados a endometriosis
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
ES2706428T3 (es) * 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
CN104540848B (zh) * 2012-08-08 2019-05-31 罗切格利卡特公司 白介素-10融合蛋白及其用途
TWI499426B (zh) * 2012-09-27 2015-09-11 Philogen Spa 與發炎性腸病有關之抗原
PT2903629T (pt) 2012-10-03 2019-09-10 Philogen Spa Conjugado de anticorpo para utilização no tratamento de uma doença inflamatória do intestino
CA2935665A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
RU2018105687A (ru) 2015-07-16 2019-08-16 Филоджен С.П.А. Иммуноконъюгаты на основе il22
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
JP2017197558A (ja) * 2017-06-07 2017-11-02 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
CN110997718B (zh) 2017-06-07 2023-11-10 菲洛根股份公司 血管内皮生长因子/抗纤连蛋白抗体融合蛋白
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
JP2022524018A (ja) * 2019-03-06 2022-04-27 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CN116322785A (zh) 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白
US20230285585A1 (en) 2020-07-22 2023-09-14 Philogen S.P.A. Treatment of pulmonary hypertension
CN113480636B (zh) * 2021-06-23 2023-11-03 烟台科瑞斯生物技术有限责任公司 重组人纤连蛋白及其制备、活性测定和稳定性实验方法
EP4493210A1 (en) 2022-03-17 2025-01-22 Universitätsklinikum Jena Anti-ed-a antibodies for the treatment of pulmonary hypertension

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571679A (en) * 1991-03-26 1996-11-05 Otsuka Pharmaceutical Factory, Inc. Anti-EDA monoclonal antibody and a method for diagnosis of disease associated with the EDA region of fibronectin
RU2280254C2 (ru) * 2000-09-07 2006-07-20 Шеринг Акциенгезельшафт РЕЦЕПТОР EDb-ДОМЕНА ФИБРОНЕКТИНА
US20060188501A1 (en) * 2000-04-06 2006-08-24 Kyowa Hakko Kogyo Co., Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
WO2006119897A2 (en) * 2005-05-11 2006-11-16 Philogen S.P.A Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) * 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
AU6098994A (en) 1993-01-27 1994-08-15 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
DK1719528T3 (da) 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
US6780594B2 (en) * 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
WO2004032857A2 (en) * 2002-10-08 2004-04-22 Immunomedics, Inc. Antibody therapy
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CA2523452A1 (en) 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
EP1660519B1 (en) 2003-07-29 2014-05-14 Immunomedics, Inc. Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US20060024757A1 (en) 2004-07-30 2006-02-02 Robert Hussa Detection of oncofetal fibronectin for selection of concepti
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
BRPI0517967B8 (pt) 2004-11-09 2021-05-25 Philogen Spa anticorpo isolado que liga-se a tenascina-c humana
EA013967B1 (ru) * 2004-12-23 2010-08-30 Мольмед Спа Продукт конъюгации
WO2007001940A2 (en) 2005-06-23 2007-01-04 Emory University Imaging agents
CA2650953A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
BRPI0709787A2 (pt) * 2006-05-08 2011-03-29 Philogen Spa citocinas com anticorpos alvejados para terapia
EA036322B1 (ru) * 2007-04-02 2020-10-26 Филоджен С.П.А. Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов
BRPI0812765B8 (pt) * 2007-07-25 2022-12-27 Philogen Spa Usos de um anticorpo que se liga à isoforma com domínio-a extra (ed-a) de fibronectina
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
PT3281952T (pt) 2007-10-30 2020-07-23 Philogen Spa Um antigénio associado a artrite reumatoide
AU2009336800A1 (en) 2009-01-07 2011-07-21 Philogen S.P.A. Cancer treatment
ES2549362T3 (es) 2009-01-07 2015-10-27 Philogen S.P.A. Antígenos asociados a endometriosis
BR112013007160A2 (pt) 2010-09-29 2016-06-14 Philogen Spa ligante tiazolidina para a conjugação de fármacos a anticorpos
ES2706428T3 (es) 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
PT2903629T (pt) 2012-10-03 2019-09-10 Philogen Spa Conjugado de anticorpo para utilização no tratamento de uma doença inflamatória do intestino
WO2014174105A1 (en) 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
AU2014257906A1 (en) 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571679A (en) * 1991-03-26 1996-11-05 Otsuka Pharmaceutical Factory, Inc. Anti-EDA monoclonal antibody and a method for diagnosis of disease associated with the EDA region of fibronectin
US20060188501A1 (en) * 2000-04-06 2006-08-24 Kyowa Hakko Kogyo Co., Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
RU2280254C2 (ru) * 2000-09-07 2006-07-20 Шеринг Акциенгезельшафт РЕЦЕПТОР EDb-ДОМЕНА ФИБРОНЕКТИНА
WO2006119897A2 (en) * 2005-05-11 2006-11-16 Philogen S.P.A Fusion protein of antibody l19 against fibronectin ed-b and interleukin 12

Also Published As

Publication number Publication date
ES2646228T3 (es) 2017-12-12
NO2209805T3 (cg-RX-API-DMAC7.html) 2018-02-03
BRPI0818272B8 (pt) 2021-05-25
EP2209805A1 (en) 2010-07-28
US20190352384A1 (en) 2019-11-21
BRPI0818272B1 (pt) 2021-01-12
JP6198703B2 (ja) 2017-09-20
KR20100101587A (ko) 2010-09-17
DK3281952T3 (da) 2020-08-03
PL2209805T3 (pl) 2018-01-31
EP3281952A1 (en) 2018-02-14
EP2209805B1 (en) 2017-09-06
US20100260707A1 (en) 2010-10-14
AU2008317941B2 (en) 2015-01-22
RU2649368C2 (ru) 2018-04-02
WO2009056268A1 (en) 2009-05-07
DK2209805T3 (en) 2017-10-16
SI3281952T1 (sl) 2020-09-30
CA2704296C (en) 2017-08-22
BRPI0818272A2 (pt) 2015-04-14
RU2013115891A (ru) 2014-10-20
JP2013040183A (ja) 2013-02-28
KR101608544B1 (ko) 2016-04-01
JP5106635B2 (ja) 2012-12-26
US10385121B2 (en) 2019-08-20
CA2704296A1 (en) 2009-05-07
MX2010004726A (es) 2010-05-20
US20170298122A1 (en) 2017-10-19
KR102002739B1 (ko) 2019-07-23
JP6154594B2 (ja) 2017-06-28
PT2209805T (pt) 2017-11-14
CN101918443B (zh) 2013-07-17
PT3281952T (pt) 2020-07-23
CN101918443A (zh) 2010-12-15
US8222377B2 (en) 2012-07-17
ES2807753T3 (es) 2021-02-24
KR20180027640A (ko) 2018-03-14
KR101836968B1 (ko) 2018-03-12
CN103396483A (zh) 2013-11-20
AU2008317941A1 (en) 2009-05-07
US9556257B2 (en) 2017-01-31
JP2011502137A (ja) 2011-01-20
JP2015091799A (ja) 2015-05-14
EP3281952B1 (en) 2020-06-24
HUE037036T2 (hu) 2018-08-28
RU2010121874A (ru) 2011-12-10
SI2209805T1 (sl) 2017-11-30
EP3783019A1 (en) 2021-02-24
CN103396483B (zh) 2016-11-23
HUE050038T2 (hu) 2020-11-30
KR20160039305A (ko) 2016-04-08
US20120244114A1 (en) 2012-09-27
PL3281952T3 (pl) 2020-11-16

Similar Documents

Publication Publication Date Title
RU2486198C2 (ru) Антиген, ассоциированный с ревматоидным артритом
JP2011502137A5 (cg-RX-API-DMAC7.html)
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
JP2010523541A5 (cg-RX-API-DMAC7.html)
ATE516819T1 (de) Verfahren zur behandlung von b-zell-bedingtem krebs
RU2015144186A (ru) Очистка конъюгата антитело-лекарственное средство (аdс)
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
RU2013142004A (ru) Конъюгаты "антитело-лекарственное средство"
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
RU2011144312A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА
JP2008528638A5 (cg-RX-API-DMAC7.html)
JP2015503909A5 (cg-RX-API-DMAC7.html)
JP2018512435A (ja) Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
RU2015107889A (ru) Композиция, содержащая два антитела, сконструированных так, чтобы они обладали пониженной и повышенной эффекторной функцией
JP2017522861A5 (cg-RX-API-DMAC7.html)
IL259036A (en) asct2-specific binding molecules and their uses
JP2010534237A5 (cg-RX-API-DMAC7.html)
JP2020522280A5 (cg-RX-API-DMAC7.html)
JP2020522281A5 (cg-RX-API-DMAC7.html)
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
RU2011142183A (ru) Средство для лечения ревматоидного артрита
RU2017112703A (ru) Составы на основе антител
JP2020510039A5 (cg-RX-API-DMAC7.html)
RU2012108108A (ru) Концентрированные полипептидные лекарственные формы с пониженной вязкостью